The prevalence or degree of AD pathology shall be higher in a subgroup with APOE-ε4 allele[s] than in those without, which means that the ROR of AEs measured in this study may partially reflect the effect of developing AE by mixed-in non-AD pathology or by the degree of amyloid or tau burden (Sato et al., 2019). Here, MAPT is linked to Alzheimer disease.